Post-Traumatic Stress Disorder Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major post-traumatic stress disorder markets reached a value of US$ 1.8 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 3.2 Billion by 2034, exhibiting a growth rate (CAGR) of 5.18% during 2024-2034.
The post-traumatic stress disorder market has been comprehensively analyzed in IMARC's new report titled "Post-Traumatic Stress Disorder Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Post-traumatic stress disorder (PTSD) refers to a mental health condition characterized by a range of symptoms that persist for an extended period of time, causing significant discomfort and impairing daily functioning. Some of the indications include intrusive thoughts or memories of the traumatic event, flashbacks, nightmares, and intense distress when exposed to reminders of the trauma. Various avoidance behaviors, such as avoiding certain places, activities, conversations, etc., related to the trauma are common. Individuals suffering from PTSD may experience negative changes in mood and cognition, including feelings of guilt or shame, diminished interest in activities, distorted beliefs about themselves or the world, etc. Hyperarousal indications, such as difficulty sleeping, irritability, hypervigilance, exaggerated startle response, etc., are also prevalent. The diagnostic process typically includes a comprehensive evaluation of the patient's symptoms and medical history. The clinician will use the criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) to determine if the indications meet the criteria for a PTSD prognosis. The assessment may involve interviews, questionnaires, and psychological evaluations to gather information and make an accurate diagnosis.
The increasing cases of direct trauma exposure, which include experiencing or witnessing situations like combat, sexual assault, natural disasters, accidents, serious injuries, etc., are primarily driving the post-traumatic stress disorder market. Moreover, the rising prevalence of numerous associated risk factors, such as pre-existing mental health conditions, certain personality traits, including a tendency to experience heightened levels of anxiety, alterations in the stress response system, etc., is further creating a positive outlook for the market. Besides this, the widespread adoption of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) to alleviate various symptoms, such as anxiety, depression, sleep disturbances, etc., is acting as another significant growth-inducing factor. Furthermore, the escalating usage of eye movement desensitization and reprocessing (EMDR) therapy, which involves bilateral stimulation, including eye movements, auditory tofnes, tapping, etc., for facilitating the processing and integration of traumatic experiences, thereby lowering their emotional impact, is also bolstering the market growth. Additionally, the emerging popularity of mindfulness-based interventions that focus on cultivating present-moment awareness, non-judgmental acceptance, and self-compassion while helping patients regulate emotions, reduce rumination as well as improve overall well-being is expected to drive the post-traumatic stress disorder market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the post-traumatic stress disorder market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for post-traumatic stress disorder and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the post-traumatic stress disorder market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the post-traumatic stress disorder market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the post-traumatic stress disorder market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current post-traumatic stress disorder marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the post-traumatic stress disorder market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the post-traumatic stress disorder market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the post-traumatic stress disorder market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of post-traumatic stress disorder across the seven major markets?
What is the number of prevalent cases (2018-2034) of post-traumatic stress disorder by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of post-traumatic stress disorder by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with post-traumatic stress disorder across the seven major markets?
What is the size of the post-traumatic stress disorder patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of post-traumatic stress disorder?
What will be the growth rate of patients across the seven major markets?
Post-Traumatic Stress Disorder: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for post-traumatic stress disorder drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the post-traumatic stress disorder market?
What are the key regulatory events related to the post-traumatic stress disorder market?
What is the structure of clinical trial landscape by status related to the post-traumatic stress disorder market?
What is the structure of clinical trial landscape by phase related to the post-traumatic stress disorder market?
What is the structure of clinical trial landscape by route of administration related to the post-traumatic stress disorder market?
The post-traumatic stress disorder market has been comprehensively analyzed in IMARC's new report titled "Post-Traumatic Stress Disorder Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Post-traumatic stress disorder (PTSD) refers to a mental health condition characterized by a range of symptoms that persist for an extended period of time, causing significant discomfort and impairing daily functioning. Some of the indications include intrusive thoughts or memories of the traumatic event, flashbacks, nightmares, and intense distress when exposed to reminders of the trauma. Various avoidance behaviors, such as avoiding certain places, activities, conversations, etc., related to the trauma are common. Individuals suffering from PTSD may experience negative changes in mood and cognition, including feelings of guilt or shame, diminished interest in activities, distorted beliefs about themselves or the world, etc. Hyperarousal indications, such as difficulty sleeping, irritability, hypervigilance, exaggerated startle response, etc., are also prevalent. The diagnostic process typically includes a comprehensive evaluation of the patient's symptoms and medical history. The clinician will use the criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) to determine if the indications meet the criteria for a PTSD prognosis. The assessment may involve interviews, questionnaires, and psychological evaluations to gather information and make an accurate diagnosis.
The increasing cases of direct trauma exposure, which include experiencing or witnessing situations like combat, sexual assault, natural disasters, accidents, serious injuries, etc., are primarily driving the post-traumatic stress disorder market. Moreover, the rising prevalence of numerous associated risk factors, such as pre-existing mental health conditions, certain personality traits, including a tendency to experience heightened levels of anxiety, alterations in the stress response system, etc., is further creating a positive outlook for the market. Besides this, the widespread adoption of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) to alleviate various symptoms, such as anxiety, depression, sleep disturbances, etc., is acting as another significant growth-inducing factor. Furthermore, the escalating usage of eye movement desensitization and reprocessing (EMDR) therapy, which involves bilateral stimulation, including eye movements, auditory tofnes, tapping, etc., for facilitating the processing and integration of traumatic experiences, thereby lowering their emotional impact, is also bolstering the market growth. Additionally, the emerging popularity of mindfulness-based interventions that focus on cultivating present-moment awareness, non-judgmental acceptance, and self-compassion while helping patients regulate emotions, reduce rumination as well as improve overall well-being is expected to drive the post-traumatic stress disorder market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the post-traumatic stress disorder market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for post-traumatic stress disorder and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the post-traumatic stress disorder market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the post-traumatic stress disorder market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the post-traumatic stress disorder market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current post-traumatic stress disorder marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the post-traumatic stress disorder market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the post-traumatic stress disorder market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the post-traumatic stress disorder market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of post-traumatic stress disorder across the seven major markets?
What is the number of prevalent cases (2018-2034) of post-traumatic stress disorder by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of post-traumatic stress disorder by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with post-traumatic stress disorder across the seven major markets?
What is the size of the post-traumatic stress disorder patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of post-traumatic stress disorder?
What will be the growth rate of patients across the seven major markets?
Post-Traumatic Stress Disorder: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for post-traumatic stress disorder drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the post-traumatic stress disorder market?
What are the key regulatory events related to the post-traumatic stress disorder market?
What is the structure of clinical trial landscape by status related to the post-traumatic stress disorder market?
What is the structure of clinical trial landscape by phase related to the post-traumatic stress disorder market?
What is the structure of clinical trial landscape by route of administration related to the post-traumatic stress disorder market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 POST-TRAUMATIC STRESS DISORDER - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 POST-TRAUMATIC STRESS DISORDER - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 POST-TRAUMATIC STRESS DISORDER - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 POST-TRAUMATIC STRESS DISORDER - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 POST-TRAUMATIC STRESS DISORDER - UNMET NEEDS
10 POST-TRAUMATIC STRESS DISORDER - KEY ENDPOINTS OF TREATMENT
11 POST-TRAUMATIC STRESS DISORDER - MARKETED PRODUCTS
11.1 List of Post-Traumatic Stress Disorder Marketed Drugs Across the Top 7 Markets
11.1.1 Paxil (Paroxetine) - Novo Nordisk
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Zoloft (Sertraline) - Pfizer
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 POST-TRAUMATIC STRESS DISORDER - PIPELINE DRUGS
12.1 List of Post-Traumatic Stress Disorder Pipeline Drugs Across the Top 7 Markets
12.1.1 JZP150 - Jazz Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 COMP 360 - COMPASS Pathways
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 BNC210 - Bionomics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Brexpiprazole - Lundbeck/Otsuka
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 LuAG06466 - Lundbeck A/S
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. POST-TRAUMATIC STRESS DISORDER - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. POST-TRAUMATIC STRESS DISORDER – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 POST-TRAUMATIC STRESS DISORDER - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Post-Traumatic Stress Disorder - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Post-Traumatic Stress Disorder - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Post-Traumatic Stress Disorder - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Post-Traumatic Stress Disorder - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Post-Traumatic Stress Disorder - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Post-Traumatic Stress Disorder - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Post-Traumatic Stress Disorder - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Post-Traumatic Stress Disorder - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Post-Traumatic Stress Disorder - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Post-Traumatic Stress Disorder - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Post-Traumatic Stress Disorder - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Post-Traumatic Stress Disorder - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Post-Traumatic Stress Disorder - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Post-Traumatic Stress Disorder - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Post-Traumatic Stress Disorder - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Post-Traumatic Stress Disorder - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Post-Traumatic Stress Disorder - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Post-Traumatic Stress Disorder - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Post-Traumatic Stress Disorder - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Post-Traumatic Stress Disorder - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Post-Traumatic Stress Disorder - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Post-Traumatic Stress Disorder - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Post-Traumatic Stress Disorder - Access and Reimbursement Overview
16 POST-TRAUMATIC STRESS DISORDER - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 POST-TRAUMATIC STRESS DISORDER MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 POST-TRAUMATIC STRESS DISORDER MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 POST-TRAUMATIC STRESS DISORDER - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 POST-TRAUMATIC STRESS DISORDER - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 POST-TRAUMATIC STRESS DISORDER - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 POST-TRAUMATIC STRESS DISORDER - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 POST-TRAUMATIC STRESS DISORDER - UNMET NEEDS
10 POST-TRAUMATIC STRESS DISORDER - KEY ENDPOINTS OF TREATMENT
11 POST-TRAUMATIC STRESS DISORDER - MARKETED PRODUCTS
11.1 List of Post-Traumatic Stress Disorder Marketed Drugs Across the Top 7 Markets
11.1.1 Paxil (Paroxetine) - Novo Nordisk
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Zoloft (Sertraline) - Pfizer
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 POST-TRAUMATIC STRESS DISORDER - PIPELINE DRUGS
12.1 List of Post-Traumatic Stress Disorder Pipeline Drugs Across the Top 7 Markets
12.1.1 JZP150 - Jazz Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 COMP 360 - COMPASS Pathways
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 BNC210 - Bionomics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Brexpiprazole - Lundbeck/Otsuka
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 LuAG06466 - Lundbeck A/S
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. POST-TRAUMATIC STRESS DISORDER - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. POST-TRAUMATIC STRESS DISORDER – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 POST-TRAUMATIC STRESS DISORDER - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Post-Traumatic Stress Disorder - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Post-Traumatic Stress Disorder - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Post-Traumatic Stress Disorder - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Post-Traumatic Stress Disorder - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Post-Traumatic Stress Disorder - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Post-Traumatic Stress Disorder - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Post-Traumatic Stress Disorder - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Post-Traumatic Stress Disorder - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Post-Traumatic Stress Disorder - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Post-Traumatic Stress Disorder - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Post-Traumatic Stress Disorder - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Post-Traumatic Stress Disorder - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Post-Traumatic Stress Disorder - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Post-Traumatic Stress Disorder - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Post-Traumatic Stress Disorder - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Post-Traumatic Stress Disorder - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Post-Traumatic Stress Disorder - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Post-Traumatic Stress Disorder - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Post-Traumatic Stress Disorder - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Post-Traumatic Stress Disorder - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Post-Traumatic Stress Disorder - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Post-Traumatic Stress Disorder - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Post-Traumatic Stress Disorder - Access and Reimbursement Overview
16 POST-TRAUMATIC STRESS DISORDER - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 POST-TRAUMATIC STRESS DISORDER MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 POST-TRAUMATIC STRESS DISORDER MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
